Igor Correia de Almeida
Corporate Officer/Principal bei SeneXta Therapeutics SA
Profil
Igor Correia de Almeida is currently the Director-Executive Board at SeneXta Therapeutics SA since 2008 and an Associate Professor at The University of Texas at Austin since 2004.
He was previously an Assistant Professor at the University of Sao Paulo from 1999 to 2004 and a Lecturer at Einstein Albert Jewish Hospital Nursing School from 1989 to 1993.
He received his graduate degree from the University of Sao Paulo in 1989, his doctorate from the same institution in 1994, and his undergraduate degree from the University of Brasília in 1981.
Aktive Positionen von Igor Correia de Almeida
Unternehmen | Position | Beginn |
---|---|---|
SeneXta Therapeutics SA
SeneXta Therapeutics SA Medical SpecialtiesHealth Technology SeneXta Therapeutics SA engages in the research and development of therapies for neurodegenerative disorders. The firm provides medicines that maintain healthy brain ageing and rehabilitation after ischemic brain injury. The company was founded by Enrico Braglia and Federica Pericle in 2008 and is headquartered in Lugano, Switzerland. | Corporate Officer/Principal | 18.09.2009 |
The University of Texas at Austin | Corporate Officer/Principal | 18.09.2009 |
Ehemalige bekannte Positionen von Igor Correia de Almeida
Unternehmen | Position | Ende |
---|---|---|
University of Sao Paulo | Corporate Officer/Principal | 01.10.2004 |
Einstein Albert Jewish Hospital Nursing School | Corporate Officer/Principal | 01.03.1993 |
Ausbildung von Igor Correia de Almeida
University of Sao Paulo | Graduate Degree |
University of Brasília | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
SeneXta Therapeutics SA
SeneXta Therapeutics SA Medical SpecialtiesHealth Technology SeneXta Therapeutics SA engages in the research and development of therapies for neurodegenerative disorders. The firm provides medicines that maintain healthy brain ageing and rehabilitation after ischemic brain injury. The company was founded by Enrico Braglia and Federica Pericle in 2008 and is headquartered in Lugano, Switzerland. | Health Technology |
Einstein Albert Jewish Hospital Nursing School |